The company announced statistically significant trial results beating standard therapy with 6.9 months vs 3.1 months median PFS, 58% risk reduction in disease progression, and higher response rates (37.1% vs 5.8%). Stock surged 26.36% in premarket trading and is trading near 52-week highs, reflecting strong investor confidence in the drug candidate's commercial potential.
Also mentions IDYA
Articles that tag IDYA but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
